Prenatal care spotlight: The double marker test.

Dr. Manisha Dadlani
4 days ago
9 min read

1. Overview

The double marker test is a crucial prenatal assessment tool used during the first trimester of pregnancy. Its main purpose is to detect pregnancies that are at elevated risk for the onset of chromosomal disorders. The test integrates maternal age with particular biochemical indicators to evaluate fetal well-being (1).

The double marker test, also known as the double test, measures two serum markers: free beta-human chorionic gonadotropin (free beta-hCG) and pregnancy-associated plasma protein A (PAPP-A). Healthcare professionals can statistically estimate the genetic abnormalities by analyzing the markers (1).

The test tracks the biochemical signals generated by the trophoblast and placenta (2,3). These signals offer insights into the progression of the fetal chromosomal framework and provide an early glimpse into the welfare of the placental-fetal unit (1).

The focus of the double marker test is on early recognition and clear risk categorization. It enables medical providers to recognize fetuses that may be at hazard for Trisomy 21 and Trisomy 18 (1).Early detection equips parents with the information needed to make educated decisions (2).

The primary aim of the double marker test is to monitor the chromosomal stability of the fetus. It also evaluates the functional ability of the placenta to facilitate fetal development (3). Deviant levels frequently indicate placental insufficiency or vascular issues (1).

2. Who should undergo the double marker test?

The double marker test is recommended in the following individuals (1,2).

All expectant mothers: Current medical guidelines recommend first‑trimester evaluations for every pregnant woman (2).
Advanced Maternal Age (AMA): Women over the age of 35 have the highest threat of chromosomal complications and should undergo this test (1).
Tobacco users: Maternal smoking significantly alters biochemical markers and necessitates recalibrated risk assessments (1).
Patients with diabetes: Pre-existing maternal diabetes can influence serum marker levels and should be documented (1).
IVF conception: Pregnancies achieved through in vitro fertilization (IVF) may show slight variations in marker levels compared to natural conception (1).

Symptom and concern checklist (Red Flags)

Mothers aged 35 or older at the time of delivery (1).
Unusual findings during a first-trimester ultrasound examination (1).
History of genetic conditions or chromosomal irregularities in past pregnancies (1).
Family history of birth defects or neural tube disorders (2).
Pregnancies conceived through assisted reproductive methods such as IVF (In vitro fertilization) or ICSI (intracytoplasmic sperm injection) (1).
Persistent maternal concerns regarding the fetus's health or genetic well-being (2).

3. When is the double marker test recommended?

Timing is crucial for ensuring the accuracy of the double marker test during pregnancy. The optimal window for this screening is between 10 and 13 weeks of gestation (1). Conducting the test outside this specific timeframe can lead to significant errors in result interpretation (2).

4. How often should the double marker Test be done?

Non-invasive prenatal testing (NIPT) is generally recommended once per pregnancy, between 10 and 13 weeks, to evaluate chromosomal risk (1,2).

For women of advanced maternal age (over 35), the test is recommended during the first trimester as a primary screening method due to the increased threat of Trisomy 21 (1).

In cases of unusual ultrasound findings such as increased nuchal translucency, the test is usually performed once, ideally on the same day, to complement imaging results (1,2).

In cases of twin pregnancies and those with a history of genetic complications, screening is usually conducted once. However, results in twins may be less sensitive, and women with prior genetic concerns may require follow-up through early invasive diagnostic screening (1, 2).

5. What conditions can the double marker test reveal?

The double marker test is primarily used to screen for specific chromosomal and developmental disorders listed below. It important to note that this is a screening tool, not a diagnostic test, and its purpose is to identify individuals who may require further evaluation (1, 2).

Trisomy 21 (Down Syndrome): The most common condition detected, characterized by an extra copy of chromosome 21 (1). It is often associated with elevated beta-hCG and reduced PAPP-A levels (2).
Trisomy 18 (Edwards Syndrome): A severe chromosomal disorder involving chromosome 18, often associated with significant developmental delays. It is usually characterized by markedly reduced levels of both serum markers (1).
Intrauterine Growth Restriction (IUGR): Low levels of PAPP-A are a strong predictor of potential fetal growth complications. This condition results from impaired placental blood flow and reduced nutrient transfer (3).
Placental Insufficiency: Abnormal marker levels may indicate complications such as preeclampsia or placental detachment later in pregnancy (1).
Trisomy 13 (Patau Syndrome): Although less common, the double marker Test can provide insights into the threat of this chromosomal abnormality (2).
Confined Placental Mosaicism (CPM): Abnormal biochemical markers may indicate the presence of genetically distinct cell populations restricted to the placenta (1).

6. What does the double marker test measure?

The double marker test measures two key glycoproteins in the mother’s blood sample, using automated immunoassay systems to ensure high accuracy (1).

Free Beta-Human Chorionic Gonadotropin (free beta-hCG): This hormone is produced by the placental syncytiotrophoblast and can be detected in maternal circulation as early as 9-10 days after ovulation (3).
PAPP-A: Produced in large amounts by the trophoblast, this zinc-dependent enzyme acts as a metalloproteinase, regulating the bioavailability of insulin-like growth factors (IGF) (3).
Nuchal Translucency (NT) - Optional but Advised: Although not a blood-based marker, NT measurement via ultrasound is often combined with the two biochemical markers (2). This integrated approach, known as the “Combined Test”, significantly enhances screening sensitivity (1).

7. Normal values in the double marker test

The normal values in the double marker test are usually expressed as Multiples of the Median (MoM). This standardization adjusts for variables such as maternal weight, smoking status, and precise gestational age, ensuring more accurate interpretation (1).

Essential first‑trimester parameters include PAPP‑A, free β‑hCG, and nuchal translucency, each assessed against established reference standards. PAPP‑A usually averages around 2.166 mIU/mL in healthy young populations and is considered normal when close to 1.0 MoM (1).

Free β‑hCG generally falls within 2–200 ng/mL, with values near 1.0 MoM indicating typical results in unaffected pregnancies (1). Nuchal translucency is usually less than 3.0 mm, with higher measurements associated with an increased statistical probability of Down syndrome (2).

PAPP‑A levels naturally rise as pregnancy progresses (1,3).In contrast, free β‑hCG peaks toward the end of the first trimester before declining (3).Final corrected MoM values are calculated using specialized statistical software such as PRISCA v4.0 (1).

8. Interpretation of double marker test results

A double marker test report provides a statistical risk estimate rather than a definitive ‘yes’ or ‘no’ result. The values are compared against established cut‑off thresholds to determine whether a pregnancy is classified as high risk (1).

Fluctuations in early‑trimester screening markers can indicate a range of genetic or pregnancy‑related risks. Elevated free β‑hCG concentrations (>2.0 MoM) are associated with an increased risk of Trisomy 21 (Down syndrome), while reduced levels may suggest Trisomy 18 or placental dysfunction (1,4). Low PAPP‑A values (<0.5 MoM) are linked to higher risks of Trisomy 21, Trisomy 18, and intrauterine growth restriction (IUGR) (3). In contrast, elevated PAPP‑A levels are generally considered a benign variation and are not associated with adverse outcomes (1).

A negative double marker test result indicates that the calculated risk is below the defined cut‑off, while a positive result means the risk exceeds it. For Trisomy 21 (Down syndrome), the typical cut‑off is 1 in 250, whereas for Trisomy 18, it is 1 in 100 (1).

9. Risks and limitations of the double marker test

Possible risks and issues

Emotional Stress: A high‑risk outcome can cause significant anxiety for parents while awaiting further evaluation (2).
Invasive Follow‑up: High‑risk results may lead to unnecessary invasive procedures, such as amniocentesis (2).
False positives: Around 5% of healthy pregnancies may be incorrectly categorized as high risk (1,2).
False negatives: Some affected pregnancies may still yield a “low‑risk” result (1).

Understanding the Limitations

Screening only: The test is not diagnostic and cannot confirm a condition (2).
Gestational dating sensitivity: Accuracy depends heavily on precise gestational age determination via ultrasound (1, 2).
Laboratory variability: Different analyzer platforms (e.g., Immulite 1000 vs. 2000) may introduce slight measurement biases (1).
Restricted scope: The test does not detect neural tube defects or all genetic abnormalities (2).
Maternal factors: Variables such as obesity, smoking, and ethnicity can influence marker levels and complicate interpretation (1).

10. Follow-up tests after a high-risk double marker test

When double marker test results indicate a significant risk, further diagnostic and supplemental evaluations are recommended (1).

Nuchal Translucency (NT) scan: A specialized ultrasound to measure the fluid‑filled space at the back of the fetal neck (4).
Noninvasive Prenatal Testing (NIPT): A highly accurate screening that analyzes cell‑free fetal DNA in maternal blood (2).
Chorionic Villus Sampling (CVS): An invasive diagnostic procedure performed between 10-13 weeks to collect placental tissue for genetic analysis (2).
Amniocentesis: A diagnostic test conducted after 14 weeks that examines fetal cells obtained from amniotic fluid (2).
Alpha‑Fetoprotein (AFP) screening: Recommended in the second trimester to specifically assess for neural tube defects (2).
Targeted Ultrasonography: High‑resolution imaging used to detect “soft markers” associated with chromosomal abnormalities (2).

11. Frequently asked questions on the double marker test

1. How do the double marker and triple marker tests differ?

The double marker test is performed in the first trimester (weeks 10–13) and evaluates two biochemical indicators (1). The triple marker test, by contrast, is conducted in the second trimester (weeks 15–20) and measures AFP, hCG, and estriol levels (2).

2. How does an NT scan compare to a double marker test?

An NT scan is an ultrasound that measures the thickness at the back of the fetus’s neck. The double marker test is a blood‑based biochemical screening. When combined, they achieve a detection accuracy of 85–90% (2).

3. Is the double marker test mandatory?

No. While not compulsory, organizations such as ACOG recommend offering it to all expectant mothers, regardless of age. The decision ultimately rests with the parents (2).

4. Can the double marker test be performed after 14 weeks?

No. PAPP‑A and free β‑hCG levels change significantly in the second trimester (1). After 14 weeks, other screenings such as the Quad test are more appropriate (2).

5. What constitutes normal age‑related risk in a double marker test?

The prospect of chromosomal abnormalities increases with maternal age, particularly after 35 (1). A common cut‑off for “high risk” is 1 in 270, which corresponds to the risk profile of a 35‑year‑old woman (2).

6. What is the primary indicator of Down syndrome?

No single marker is definitive. However, elevated free β‑hCG combined with markedly low PAPP‑A is the most critical biochemical sign (2). Increased nuchal translucency (>3.0 mm) is the key ultrasound indicator (4).

7. What causes Down syndrome, and can it be prevented?

Down syndrome results from a random error in cell division (nondisjunction), leading to an extra chromosome 21. It cannot be prevented through lifestyle changes, as it is an unpredictable genetic event (1).

8. Is the double marker test safe for the fetus?

Yes. It poses no risk to the baby since it only requires a maternal blood sample. Unlike CVS or amniocentesis, it carries no threat of miscarriage or fetal harm (2).

9. What does “Multiples of the Median” (MoM) mean in my report?

MoM is a statistical measure showing how far a result deviates from the median for a given gestational age. A MoM of 1.0 means the value is exactly at the median (1).

10. Why are weight and smoking habits considered in this test?

Maternal factors can influence marker levels. Smoking may reduce PAPP‑A by about 17%, while higher body weight can dilute marker concentrations (1)

About the Author

Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.

References:

Liteanu A, Mihhùan M, Artenie V. The importance of the double test in the identification of high-risk pregnancies for chromosomal diseases development. Analele Științifice ale Universității „Alexandru Ioan Cuza”, Secțiunea Genetică și Biologie Moleculară. 2011; XII:31-37.
Dungan JS. Noninvasive prenatal fetal screening tests. MSD Manual Professional Edition. Available at: https://www.msdmanuals.com/professional/gynecology-and-obstetrics/prenatal-genetic-counseling-and-evaluation/noninvasive-prenatal-fetal-screening-tests Accessed on 8th April, 2026.
Ceballos Medina A, Gómez-Acebo I, Gallego de Largy CC, et al. Study of first-trimester serum levels of β-hCG and PAPP-A as a screening test for fetal development of intrauterine growth restriction. BMC Pregnancy Childbirth. 2025; 25:655. doi:10.1186/s12884-025-07787-7
Ziolkowska K, Dydowicz P, Sobkowski M, Tobola-Wrobel K, Wysocka E, Pietryga M. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. Ginekol Pol. 2019;90(3):161-166. doi:10.5603/GP.2019.0029

Disclaimer

The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to contact@crixus.co.in